CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast

Journal of Clinical Pathology

Volumn 58, Issue 11, 2005, Pages 1185-1188

  Tse, G M K ^a   Tan, P H ^b   Ma, T K F ^c   Gilks, C B ^d   Poon, C S P ^c   Law, B K B ^e  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c NORTH DISTRICT HOSPITAL   (Hong Kong)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e Union Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANIMAL TISSUE; ARTICLE; BREAST LESION; BREAST PAPILLOMA; CARCINOMA IN SITU; CELL DIFFERENTIATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MYOEPITHELIUM CELL; NONHUMAN; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STAINING; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMA, INTRADUCTAL; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 27644442338     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.026906     Document Type: Article

References (33)

1. Price EA, Coombe DR, Murray JC. Endothelial CD44H mediates adhesion of a melanoma cell line to quiescent human endothelial cells in vitro. Int J Cancer 1996;65:513-18.
2. Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993;184:47-63.
3. Marhaba R, Zoller M. CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 2004;35:211-31.
4. Thomas L, Byers HR, Vink J, et al. CD44H regulates tumour cell migration on hyaluronate-coated substrate. J Cell Biol 1992;118:971-7.
5. Spicer AP, Roller ML, Camper SA, et al. The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11. Genomics 1995;30:115-17.
6. Ruiz P, Schwarzler C, Gunthert U. CD44 isoforms during differentiation and development. Bioessays 1995;17:17-24.
7. Haynes BF, Liao HX, Patton KL. The transmembrane hyaluronate receptor (CD44): multiple functions, multiple forms. Cancer Cells 1991;3:347-50.
8. Bar JK, Grelewski P, Popiela A, et al. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumours: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol 2004;95:23-31.
9. Zagorianakou N, Stefanou D, Makrydimas G, et al. CD44s expression, in benign, borderline and malignant tumours of ovarian surface epithelium. Correlation with p53, steroid receptor status, proliferative indices (PCNA, MIB1) and survival. Anticancer Res 2004;24:1665-70.
10. Ioachim E, Goussia A, Agnantis NJ. Glycoprotein CD44 expression in colorectal neoplasms. An immuno-histochemical study including correlation with cathepsin D, extracellular matrix components, p53, Rb, bcl-2, c-erbB-2, EGFR and proliferation indices. Virchows Arch 1999;434:45-50.
11. Masaki T, Goto A, Sugiyama M, et al. Possible contribution of CD44 variant 6 and nuclear beta-catenin expression to the formation of budding tumour cells in patients with T1 colorectal carcinoma. Cancer 2001;92:2539-46.
12. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Gains and losses of CD44 expression during breast carcinogenesis and tumour progression. Histopathology 1998;33:107-16.
13. Friedrichs K, Franke F, Lisboa BW, et al. CD44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 1995;55:5424-33.
14. Schumacher U, Horny HP, Horst HA, et al. A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur J Surg Oncol 1996;22:259-61.
15. Guriec N, Marcellin L, Gairard B, et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metastasis 1996;14:434-9.
16. Regidor PA, Callies R, Regidor M, et al. Expression of the CD44 variant isoforms 6 and 4/5 in breast cancer. Correlation with established prognostic parameters. Arch Gynecol Obstet 1996;258:125-35.
17. Rys J, Kruczak A, Lackowska B, et al. The role of CD44v3 expression in female breast carcinomas. Pol J Pathol 2003;54:243-7.
18. Krogerus LA, Leivonen M, Haasto AL. Expression patterns of biologic markers in small breast cancers and preneoplastic breast lesions. Breast 2000;9:281-5.
19. Berner HS, Nesland JM. Expression of CD44 isoforms in infiltrating lobular carcinoma of the breast. Breast Cancer Res Treat 2001;65:23-9.
20. Saddik M, Lai R. CD44s as a surrogate marker for distinguishing intraductal papilloma from papillary carcinoma of the breast. J Clin Pathol 1999;52:862-4.
21. Bocker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part I: normal breast and benign proliferative lesions. Virchows Arch A Pathol Anat Histopathol 1992;421:315-22.
22. Bocker W, Bier B, Freytag G, et al. An immunohistochemical study of the breast using antibodies to basal and luminal keratins, alpha-smooth muscle actin, vimentin, collagen IV and laminin. Part II: epitheliosis and ductal carcinoma in situ. Virchows Arch A Pathol Anat Histopathol 1992;421:323-30.
23. Boecker W, Buerger H, Schmitz K, et al. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high molecular-weight cytokeratin expression patterns. J Pathol 2001;195:415-21.
24. Jarasch ED, Nagle RB, Kaufmann M, et al. Differential diagnosis of benign epithelial proliferations and carcinomas of the breast using antibodies to cytokeratins. Hum Pathol 1988;19:276-89.
25. Lacroix-Triki M, Mery E, Voigt JJ, et al. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 2003;442:548-54.
26. Otterbach F, Bankfalvi A, Bergner S. Cytokeratin 5/6 immunohistochemistry assists the differential diagnosis of atypical proliferations of the breast. Histopathology 2000;37:232-40.
27. Raju U, Crissman JD, Zarbo RJ, et al. Epitheliosis of the breast. An immunohistochemical characterization and comparison to malignant intraductal proliferations of the breast. Am J Surg Pathol 1990;14:939-47.
28. Stefanou D, Batistatou A, Nonni A, et al. p63 expression in benign and malignant breast lesions. Histol Histopathol 2004;19:465-71.
29. Tan PH, Aw MY, Yip G, et al. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 2005;29:625-32.
30. Sinn HP, Heider KH, Skroch-Angel P, et al. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat 1995;36:307-13.
31. Berner HS, Suo Z, Risberg B, et al. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 2003;42:546-54.
32. Wobus M, Rangwala R, Sheyn I, et al. CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells. Appl Immunohistochem Mol Morphol 2002;10:34-9.
33. Draffin JE, McFarlane S, Hill A, et al. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64:5702-11.